title: MPT-51/CpG DNA vaccine protects mice against Mycobacterium tuberculosis.
abstract: Tuberculosis (TB) is a severe infectious disease that kills approximately two million people worldwide every year. Because BCG protection is variable and does not protects adults, there is a great need for a new vaccine against TB that does not represent a risk for immunocompromised patients and that is also capable of protecting adult individuals. MPT-51 is a protein found in the genome of mycobacteria and binds to the fibronectin of the extracellular matrix, which may have a role in host tissue attachment and virulence. In order to test the usefulness of MPT-51 as a subunit vaccine, BALB/c were vaccinated and challenged with Mycobacterium tuberculosis. The infection of BALB/c with M. tuberculosis increased the number of IFN-gamma(+) T lymphocytes specific to MPT-51 in the spleen and lungs. Inoculation with rMPT-51/FIA and with rMPT-51/CpG DNA in non-infected BALB/c increased the amounts of IFN-gamma(+) T lymphocytes. Inoculation with rMPT-51/FIA also induced a humoral response specific to MPT-51. CFU counts of lung tissues done 60 days after infection showed a reduction of about 2 log in the bacteria load in the group of animals inoculated with rMPT-51/CpG DNA. These results make MPT-51 a valuable component to be further evaluated in the development of other subunit vaccines.
authors.affiliation: Instituto de Patologia Tropical e Saúde Pública da Universidade Federal de Goiás, Rua 235 esquina com 1 feminine Avenida, S/N, Setor Universitário, 74605-050 Goiânia-Goiás, Brazil.
authors.forename: Bruna Daniella de Souza
authors.initials: BD
authors.lastname: Silva
authors.forename: Ediane Batista
authors.initials: EB
authors.lastname: da Silva
authors.forename: Ivan Pereira
authors.initials: IP
authors.lastname: do Nascimento
authors.forename: Michelle Cristina Guerreiro
authors.initials: MC
authors.lastname: Dos Reis
authors.forename: André
authors.initials: A
authors.lastname: Kipnis
authors.forename: Ana Paula
authors.initials: AP
authors.lastname: Junqueira-Kipnis
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D018899:CpG Islands / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology; D008168:Lung / Q000276:immunology / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D009169:Mycobacterium tuberculosis / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014376:Tuberculosis / Q000276:immunology / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology*; D022223:Vaccines, Subunit / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C082911:MPT51 protein, Mycobacterium; D032581:Tuberculosis Vaccines; D019444:Vaccines, DNA; D022223:Vaccines, Subunit; D007371:Interferon-gamma